To that end, FATE-NK100 is being investigated in combination with two monoclonal antibodies: the anti-EGFR monoclonal antibody cetuximab in patients with advanced colorectal cancer and head and neck squamous cell cancer or the anti-HER2 monoclonal antibody trastuzumab in patients with HER2+ advanced breast, gastric or other solid cancers (DIMENSION trial NCT03319459) (from https://clinicaltrials.gov, accessed on 1 November 2024). This evidence concerns the gene ERBB2 and colorectal cancer.